Kiniksa Pharmaceuticals International PLC
KNSA
Company Profile
Business description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Contact
23 Old Bond Street
Floor 3
LondonW1S 4PZ
GBRT: +44 7814319100
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
315
Stocks News & Analysis
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
stocks
For US software stocks, it’s been an AI bust, not a boom
Once-hot software names are lagging. Are they good buys?
stocks
Finding value in the Aussie mining sector
Is the mining sector overvalued? A new Morningstar report highlights pockets of value that remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,802.50 | 40.90 | -0.46% |
| CAC 40 | 7,959.67 | 22.98 | -0.29% |
| DAX 40 | 23,239.18 | 147.31 | 0.64% |
| Dow JONES (US) | 46,448.27 | 202.86 | 0.44% |
| FTSE 100 | 9,534.91 | 4.80 | -0.05% |
| HKSE | 26,030.44 | 313.94 | 1.22% |
| NASDAQ | 22,872.01 | 598.92 | 2.69% |
| Nikkei 225 | 48,815.27 | 189.39 | 0.39% |
| NZX 50 Index | 13,487.19 | 12.66 | -0.09% |
| S&P 500 | 6,705.12 | 102.13 | 1.55% |
| S&P/ASX 200 | 8,515.50 | 48.20 | -0.56% |
| SSE Composite Index | 3,879.51 | 42.74 | 1.11% |